What's inside Elon's building in Memphis will shock you
Inside Elon Musk's Memphis site lies a supercomputer built to power the world's first superhuman AI. It could make Elon a trillionaire - and new millionaires, too. With just $500, you could get in before the July 1st funding window closes.
ProKidney Stock Shoots Up Over 8% After Hours After Staggering 515% Rally On Wednesday
ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained additional 8.58% after-hours to $4.05 on positive Phase 2 trial results, with trading volume seeing a jump to 39.8 million shares from an average of 1.12 million.
Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study
Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability across all doses.
How High Will Gold Surge? - Ad
Gold is on fire - hitting $3,500 and outpacing stocks, tech, even Bitcoin. Analyst Sean Brodrick called it, and now he's forecasting a surge to $6,900. But the biggest opportunity isn't bullion. It's a little-known investment that's returned up to 1,000x more than physical gold.
Trump Diagnosed With Chronic Venous Insufficiency, A Common Circulatory Condition In Over-70s, White House Says He's 'In Excellent Health'
The White House revealed President Trump is diagnosed with chronic health condition.
FDA names former pharmaceutical company executive to oversee US drug program
WASHINGTON (AP) — The Food and Drug Administration on Monday named a longtime pharmaceutical executive to run the agency’s drug program, the latest in a string of leadership changes at the agency.
Buffett's Favorite Chart Just Hit 209% - Here's What That Means For Gold - Ad
Buffett's favorite market signal just hit its highest level in history-stocks are more overvalued than 1929. He's sitting on $325B in cash... and may be about to buy one overlooked gold miner. I've identified it-plus 4 others with up to 100X potential.
Trump administration appeals to Supreme Court to allow $783 million research-funding cuts
WASHINGTON (AP) — The Trump administration asked the on Thursday to allow it to cut hundreds of millions of dollars’ worth of research funding in its push to roll back federal diversity, equity and inclusion efforts.
Want To Bet Bigger On UnitedHealth? Now There's A Cheaper Way
New UNHG ETF offers 200% daily exposure to UnitedHealth Group with low expense ratio. Themes ETFs adds to roster with 20 single-stock leveraged ETFs.
Apple's Secret Weapon to Disrupt a $9 Trillion Industry - Ad
Apple just fired a shot at a $9 trillion sector - not with a new iPhone, but with its most disruptive project since the smartphone. One tiny supplier - still trading near $30 - sits quietly at the center of this bold move.
These tips from experts can help your teenager navigate AI companions
As artificial intelligence technology becomes part of daily life, to chatbots for advice, guidance and conversation. The appeal is clear: Chatbots are patient, never judgmental, supportive and always available.
Sweetening soft drinks: What to know about sugar, high-fructose corn syrup and their alternatives
President Donald Trump last week, but the Coca-Cola Co. Tuesday: a cane sugar-sweetened version of the beverage maker's trademark soda will be released in the U.S. this fall.
Trump Signals "End of M.A.G.A." - Ad
Trump's new mission: Make America Wealthy Again. And according to ex-CIA advisor Jim Rickards, the U.S. is sitting on a $150 trillion fortune--enough to make every family millionaires. Discover how this hidden wealth could soon change everything.
Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths
WASHINGTON (AP) — Drugmaker said late Friday it won't comply with a request from the Food and Drug Administration to halt all shipments of receiving one of its treatments for muscular dystrophy.
Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial
Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in myelofibrosis patients.
Warren Buffett's Investing Partner's Shocking Final Move - Ad
Before he passed away, Charlie Munger, Warren Buffett's investing partner of 60 years, was rumored to have quietly made one final investment... Up until now, it has remained hidden from the public. It's potentially the smartest, most profitable, and most under-valued AI investment you can make today.
Trump says Coke will shift to cane sugar. But increasingly, shoppers want no sugar in their sodas
The debate over whether should use high-fructose corn syrup or in its signature soda obscures an important fact: Consumers are increasingly looking for Coke with no sugar at all.
Federal judge reverses rule that would have removed medical debt from credit reports
NEW YORK (AP) — A federal judge in Texas removed a Biden-era finalized ruled by the that would have removed from credit reports.
What's inside Elon's building in Memphis will shock you - Ad
Inside Elon Musk's Memphis site lies a supercomputer built to power the world's first superhuman AI. It could make Elon a trillionaire - and new millionaires, too. With just $500, you could get in before the July 1st funding window closes.
FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analyst
Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline.
Texas Judge Blocks Biden-Era Rule Meant To Erase $49 Billion In Medical Debt From Credit Reports
A judge blocked a Biden-era rule that would have removed medical debt from credit reports, siding with industry arguments that the agency overstepped its authority.
How to Hack a $1.3T Market - Ad
Forget concrete. The new foundation for real estate success is digital, and Pacaso leads the way. Their tech unlocks a $1.3T real estate market. They've already earned $110M+ in gross profits in their operating history and reserved the Nasdaq ticker PCSO.
Breakfast cereal sales declined for decades before Kellogg's sale to Italian company
Breakfast cereal could use a lucky charm.
'The Salt Path:' A book that captured the hearts of millions, but now mired in controversy
LONDON (AP) — “The Salt Path” is a memoir of resilience and courage that captured the hearts of millions and which was subsequently adapted for the big screen, with actors Gillian Anderson and Jason Isaacs taking the lead roles.
Tesla's About to Prove Everyone Wrong... Again - Ad
Back in 2018, when Jeff Brown told everyone to buy Tesla... The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
Rhythm Pharma's Oral Drug For Rare Obesity Shows Promise
Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 with regulators.
Mattel introduces its first Barbie with Type 1 diabetes
NEW YORK (AP) — Mattel has introduced its first Barbie representing a person with Type 1 diabetes, as part of wider efforts from the toy maker to increase inclusivity among its dolls.
Leaked Memo Points to $100 Trillion Wealth Transfer Starting Soon - Ad
The U.S. Department of the Interior's internal memo has leaked ... and the contents are shocking. A federally backed resource monetization plan may soon go live, and it could trigger a new gold rush into select energy and mineral stocks. Investing legend Whitney Tilson breaks it all down inside.
Medical Groups Sue RFK Jr. For Assault On Science Over Unlawful COVID-19 Vaccine Rollbacks
Major health groups sue HHS and Robert F. Kennedy Jr. over COVID-19 vaccine policy changes for children and pregnant individuals.
Business News Digest
AP Business Digest
The Tesla Shock Nobody Sees Coming - Ad
While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
Business News Digest
AP Business Digest
Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial
Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B is ongoing.
How High Will Gold Surge? - Ad
Gold is on fire - hitting $3,500 and outpacing stocks, tech, even Bitcoin. Analyst Sean Brodrick called it, and now he's forecasting a surge to $6,900. But the biggest opportunity isn't bullion. It's a little-known investment that's returned up to 1,000x more than physical gold.
Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns
Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in after-hours trading to $4.48, amid concerns of a potential NASDAQ delisting.
AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment
AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ivonescimab.
Buffett's Favorite Chart Just Hit 209% - Here's What That Means For Gold - Ad
Buffett's favorite market signal just hit its highest level in history-stocks are more overvalued than 1929. He's sitting on $325B in cash... and may be about to buy one overlooked gold miner. I've identified it-plus 4 others with up to 100X potential.
Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons
House Judiciary subpoenas ex-Pfizer exec Philip Dormitzer amid claims the COVID-19 vaccine announcement was delayed to avoid influencing the 2020 election.
House Republicans race toward a final vote on Trump's tax bill, daring critics to oppose
WASHINGTON (AP) — Republican leaders in the House are sprinting toward a Wednesday vote on President Donald Trump's , determined to seize momentum from a in the Senate while essentially daring members to defy their party's leader and vote against it.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.